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Abstract
Aim.—Empirically demonstrates the effect of varying study design choices to evaluate the safety 
of pioglitazone on bladder cancer.
Methods.—We identified Medicare beneficiaries aged >65 with diabetes between 2008 and 2015 
and classified exposure (≥2 claims within 180 days) to glucose-lowering drugs (GLD; pioglitazone 
or other). The effects of varying the following study design parameters on bladder cancer risk were 
assessed - new versus existing drug use, choice of referent (all non-users and users of GLDs, non-
insulin GLDs, and DPP-4’s), and whether or not censoring accounted for treatment change. We 
used Cox proportional hazards models to obtain adjusted HRs and 95% CI.
Results.—We included 1,510,212 patients classified as pioglitazone users (N=135,188) or non-
users (N=1,375,024). Users had more diabetic complications than non-users, but less than insulin 
users. The HR ranged from 1.10(1.01–1.20) to 1.13(0.99–1.29) when censoring ignored treatment 
changes, suggesting weak or no association between pioglitazone and bladder cancer, likely under-
estimating risk, but was 1.20(1.01–1.42) when cohorts restricted to new users, censored upon 
treatment change, and used DPP-4 as the referent, suggesting an increased risk of bladder cancer 
associated with pioglitazone.
Conclusions.—The continued demand for new GLDs compels the need for more robust 
observational methods to improve the value of the RWE generation in order to equip clinicians to 
make informed prescribing decisions. Although there is no one-size-fits-all approach, we 
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recommend active comparator new user study designs that compare therapeutically equivalent 
drugs and account for treatment changes during follow-up to present the least biased comparative 
safety estimates.
Introduction.
Diabetes affects at least one in five older adults (age ≥65) in the US and over 86% of older 
adults with diabetes will require treatment with one or more glucose-lowering drug (GLD).1 
The continued demand for new GLDs compels the need for robust observational methods to 
improve the value of real-world evidence (RWE) and better understand their comparative 
effectiveness and safety. The safety of the pioglitazone, a GLD from the thiazolidinedione 
(TZD) class, has been debated for over twenty years despite being generally well-tolerated.2 
The Food and Drug Administration (FDA) issued a safety warning that TZDs may increase 
and/or exacerbate heart failure in 2007.3 This was followed by a safety warning in 2011 that 
exposure more than two years to pioglitazone may increase the risk of bladder cancer,4 a 
warning that was later re-issued in December 2016.5
Several studies have reported on the safety of pioglitazone; many reported no evidence to 
suggest an increased risk of bladder cancer associated with pioglitazone use,6–14 while 
others reported an increased risk.15–19 The safety estimates of these studies varied widely. 
This is likely driven by the different study design choices, which obscures the association 
between pioglitazone and bladder cancer and makes it difficult to determine the actual 
safety. The majority of observational studies evaluating this association included all users of 
pioglitazone without requiring new use;6–8,11,12,17,20–26 most of which did not report 
evidence of an increased risk of bladder cancer. Very few studies compared pioglitazone to a 
single drug (or class of drugs).9,19,27 Many studies identified all diabetic patients and then 
compared patients treated with pioglitazone to one composite referent group of all non-users 
of pioglitazone. While some restricted the composite referent group to patients treated with a 
GLD7,11,17,21 or a non-insulin GLD (NIGLD)10,16,18 other than pioglitazone, many included 
both those treated and untreated with a GLD.6,8,12,20,22,23,25,26 Among the comparisons with 
referent groups that additionally included untreated patients, reports of no evidence to 
suggest an increased risk of bladder cancer was common, whereas estimates from 
comparisons to treated GLD or NIGLD referent groups had more variation. Few studies 
accounted for exposure duration6,11,17–20,26 and only two studies that we reviewed censored 
follow-up based on treatment change in addition to outcome, death, or end of study.17,19 
Few studies lagged the exposure period to allow for a sufficient time for development and 
detection of malignancy (i.e. latency period), excluding outcomes that occur immediately 
after start of treatment.16–19 Studies that accounted for exposure changes or lag/latency 
tended to identify effect estimates furthest from the null, commonly reporting an increased 
risk of bladder cancer.
Using the example of pioglitazone and bladder cancer among older adults, we sought to 
understand the impact of heterogeneity of study design on studies evaluating safety of 
diabetic medications. This paper aims to demonstrate the importance of how exposure is 
defined, what exposure is being compared to, and when to identify safety endpoints. We 
varied new versus existing drug use, the choice of the referent group (all non-pioglitazone 
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patients; users of all GLDs other than pioglitazone; users of all NIGLDs other than 
pioglitazone; and users of dipeptidyl peptidase-4 [DPP-4] inhibitors), and whether or not 
follow-up is censored according to treatment change.
Methods
Data Source.
Data was abstracted from a 20% random sample of Medicare Parts A (inpatient), B 
(outpatient) and D (prescription) adjudicated claims data from January 1, 2007 (start of 
available data) to December 31, 2015 (end of available data). Medicare provides public 
insurance to over 98% of older US adults, and contains information about demographic and 
enrollment characteristics, diagnoses, procedures, and dispensed prescriptions for enrollees.
28 Within Medicare Parts A and B, all diagnoses for medical conditions are recorded via 
ICD-9 codes on or prior to September 30, 2015 and via ICD-10 codes after. All procedures 
are recorded via Current Procedural Terminology, Fourth edition (CPT-4) or Healthcare 
Common Procedure Coding System (HCPCS) codes. Within Medicare Part D, claims for 
prescriptions dispensed are recorded via National Drug Codes (NDC).
Study Population.
In the 10-year safety study requested by the FDA, patients were selected from a diabetic 
registry and exposure was assigned hierarchically according to the first group that they 
qualified for during the cohort entry period without regard to treatment change.6 Before 
creating our varied referent groups, we attempted to mimic this design by selecting a cohort 
of patients with a diabetes diagnosis (ICD-9-CM: 250.x; 2 outpatient claims within 365 days 
or 1 inpatient claim) with at least 365 days of continuous enrollment with medical and 
prescription coverage prior to the first inpatient or second outpatient claim.
Exposure.
We identified GLD exposure based on a prescription claim for any GLD between January 
2008 and September 2015 with an NDC corresponding to an anatomical therapeutic 
chemical (ATC) classification system code starting with A10*29 and classified exposure 
according to pioglitazone or each of the non-TZD GLD classes (Table S1). Additional detail 
describing exposure can be found in the e-supplement. New use of GLD exposure was 
determined based on no prescription claims for the drug classes included in each comparison 
during the 365-day period prior to the initial claim. Each patient was then hierarchically 
assigned to one of four mutually exclusive exposure categories: Pioglitazone (≥2 claims 
within 180 days), GLD (≥2 claims within 180 days), Single GLD (only 1 GLD claim), or 
Untreated (no GLD claims). Cohort entry was defined according to the first qualifying claim 
(e.g. second if 2 required; date of diabetes claim for untreated; Figure S2). Patients aged less 
than 66 upon cohort entry or with a diagnosis of prevalent bladder cancer or common 
bladder cancer treatment procedures (Table S2) were excluded.
We then created our four varied referent groups to compare pioglitazone users to: all non-
users of pioglitazone, GLD users, non-insulin GLD (NIGLD) users, and DPP-4 users (Table 
S3). We also explored some of the components of the non-pioglitazone composite referent 
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group thought to be most influential (Table S4). All-user cohorts included all patients 
according to first qualifying referent group, and new-user cohorts included patients 
classified according to first new-user referent group that they qualify for during the cohort 
entry period.
Outcome.
Incident bladder cancer events were defined using an algorithm previously validated for 
other solid tumors in Medicare data, at least two diagnostic claims for bladder cancer within 
60 days.30 We included carcinoma in situ of the bladder (ICD-9: 233.7; ICD10: D09.0) in 
addition to all other bladder cancer (ICD-9: 188.x; ICD-10: C67.x, C79.11) diagnosis codes 
since the majority of bladder cancers are diagnosed at an early stage.31 The first claim date 
defined the event date, as thought to be closest to date of actual diagnosis.
Follow-up.
The follow-up period for identifying bladder cancer events was lagged to begin 180 days 
after the cohort entry date to allow for time between exposure and development of disease 
(induction period). By excluding cases immediately following exposure, we thereby reduce 
the potential for spurious associations attributable to increased medicalization after start of a 
therapy or the possibility of preclinical symptoms of bladder cancer influencing treatment 
choice (protopathic bias). Patients who died or had the outcome within the first 180 days of 
follow-up were excluded from the analytic cohort. We compared two censoring approaches. 
First, an “as-treated” (AT) approach that continued until first occurrence of incident bladder 
cancer, death, disenrollment of medical or prescription coverage, study end (December 
2015), or treatment discontinuation (no subsequent dispensing for initiated drug class within 
days-supply plus a 90-day grace period). An additional 6-month latency period was also 
added after treatment discontinuation to allow time for disease manifestation and detection. 
The second approach, referred to here as the “initial-treatment” (IT) approach, did not 
censor on treatment discontinuation, similar to the intent-to-treat approach used in 
randomized controlled trials. Although lag periods are typically applied following new use, 
we used the same lag period for the all user comparisons to be consistent. Given that 
pioglitazone was on the market longer than some of the newer drugs, such as DPP-4s and 
SGLT-2s, follow-up was truncated at 5 years. We analyzed overall follow-up and follow-up 
stratified at two years, based on the original FDA safety warning. Only the subset of patients 
not otherwise censored within two years were included in analyses evaluating associations 
two years after cohort entry.
Statistical Analysis and Confounding Control.
The baseline covariate assessment period prior to cohort entry was 1 year (365 days). 
Covariates were selected a priori to include demographics (age, sex, and race), year of 
cohort entry, diabetes-related complications (nephropathy, neuropathy, retinopathy), 
smoking, comorbidities, and use of GLDs and other medications of interest. We used 
descriptive statistics to summarize covariates and to describe baseline differences across 
comparisons. The crude bladder cancer incidence rates (first event per patient) were 
calculated based on the Poisson distribution overall and for each treatment category. Cox 
proportional hazards models were used to estimate the HRs and 95% CI for incident bladder 
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cancer. Crude models included treatment as the only independent variable. Partially adjusted 
models included treatment, age, sex, race, and age-squared as independent variables. To be 
consistent with the 10-year safety study requested by the FDA,6 multivariable outcome 
regression models were used to obtain fully adjusted HRs. All data were analyzed using 
SAS, v9.4. The University of North Carolina at Chapel Hill institutional review board 
approved this study.
Results.
Distribution of Patient Characteristics.
Among the 1,510,212 patients who met the entry criteria for diabetes diagnosis, 135,188 
were assigned to the pioglitazone Category 1 and 828,527 to the GLD Category 2 (Figure 1). 
Of the remaining patients, 124,100 had some GLD exposure (Category 3) and 422,397 were 
untreated. A more detailed summary of the cohort and analytic cohort attrition for all 
comparisons can be found in Supplemental Table S5. Among the all-user (Table 1) and new-
user (Table 2) comparisons, pioglitazone users were generally younger, but no appreciable 
difference in sex and race. Pioglitazone users were less likely to have a smoking-related 
claim, congestive heart failure (CHF) and prior use of loop diuretics. There were no 
clinically meaningful differences in urinary tract-related comorbidities across all 
comparisons. Other comorbidities were similar for GLD and NIGLD comparisons, but less 
prevalent in pioglitazone users. In the all-user comparisons, pioglitazone users were 
generally more likely to have prior NIGLD use and diabetic complications. These 
differences were more pronounced when pioglitazone was compared to the non-pioglitazone 
group and for all new-user comparisons, but characteristics were similar when compared to 
DPP-4 in the new-user comparison.
Incidence of Bladder Cancer.
Figure 2 illustrates the fully adjusted HRs for pioglitazone users compared to each referent 
group. Additional detail about the number of bladder cancer events and incidence rates per 
100,000 person-years, crude HRs, and HRs partially-adjusted for age, sex, and race are 
reported in Tables S6–S8. Overall, the incidence rates were fairly constant across all 
analyses ranging from 193.0–230.3 per 100,000 person-years among the all-user 
comparisons and 188.6–251.0 per 100,000 person-years in the new-user comparisons, with 
the highest rates highest rates observed in the AT analysis. Given minimal differences in age, 
sex, and race across all comparisons, partially-adjusted HRs were generally similar to crude. 
When follow-up did not account for treatment changes, the HR ranged from 1.10(1.01–1.20) 
to 1.13(0.99–1.29). When cohorts restricted to new users, follow-up accounted for treatment 
changes, and DPP-4 was used as the referent, the HR was 1.20(1.01–1.42). When follow-up 
was truncated at 2 years, the HRs increased, the greatest increase identified among the IT 
analyses. For follow-up after 2 years, there was a late-stage effect and a large increase in 
variance for all AT analyses as diabetic patients were less likely to stay on the same 
treatment for long durations, and HRs were generally attenuated for all comparisons except 
for pioglitazone versus DPP-4, where the HR became larger.
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Exploration of the Components of the Non-pioglitazone Composite Referent Group.
When we looked at some of the components of the non-pioglitazone referent group 
individually (Table S9 and S10), the untreated patients represented 31% of the all-user and 
62% of the new-user composite non-pioglitazone referent groups. Long-acting insulin users 
were more likely to have diabetic complications than pioglitazone users, metformin users, 
and the untreated, respectively. New users of metformin were younger than new users of 
pioglitazone, new users of long-acting insulin, and the untreated, respectively. Other 
comorbidities were highest among the untreated and long-acting insulin groups. Bladder 
cancer rates for the non-pioglitazone referent group (193.8–195.9 per 100,000 person-years) 
were similar to its untreated component (196.8 per 100,000 person-years), and higher than 
its metformin component (174.5–178.9 per 100,000 person-years). (Table S13–S15) Fully-
adjusted HRs for pioglitazone versus untreated were similar to pioglitazone versus the 
overall composite non-pioglitazone referent group; these HRs were higher when compared 
to metformin and highest when compared to long-acting insulin.
Discussion.
Using the example of pioglitazone and bladder cancer among older adults, this paper 
highlights how effect estimates can change due to variation of study design choices. 
Although there are many publications outlining the importance of study design choices, 
including but not limited to those advocating for the active-comparator and new user 
designs,32–36 this paper is the first to systematically vary study design to compare effect 
estimates when evaluating the safety of a diabetic medication. Similar to the trends we 
identified in the existing literature on the association between pioglitazone and bladder 
cancer and as previously suggested,32,33 we found that estimates were generally lower when 
all users were included and when treatment changes were ignored, suggesting no increased 
risk. The HRs increased to 1.20(1.01–1.42) for the new-user comparison to a clinically 
meaningful treatment alternative, DPP-4, when follow-up accounted for treatment changes. 
Important differences were identified within the composite referent group of all non-
pioglitazone patients indicating that long-acting insulin users were at different stages of 
diabetic severity than pioglitazone users, metformin users, and the untreated, respectively.
There are many reasons for variation of published estimates. When we plotted the log of all 
relative estimates of the previously published studies against the precision of each study 
(Figure S1), we identified an asymmetrical pattern, which may be attributable to publication 
bias or selective outcome reporting, but is most likely due to the heterogeneity of study 
design choices.37 When studies do not restrict to new users of index treatment(s), estimates 
may adjust for variables affected by prior treatment, which can bias estimation of treatment 
effects toward the null and under-estimate harm.32,33 Timing of outcome ascertainment is 
important especially for cancer outcomes given that the actual risk period relevant for drug-
associated cancers is poorly understood.38 When treatment is defined at baseline ignoring 
treatment changes that occur during follow-up, estimates are more susceptible to exposure 
misclassification (via non-adherence), which can attenuate results towards the null, 
potentially masking drug effects on safety outcomes. Lastly, referent choice can also 
influence both the interpretation and generalizability of comparative safety estimates, 
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because confounding by severity threatens study validity when there are major differences in 
disease severity between those prescribed the exposure and the referent.34
Many of the published studies that evaluated the association between pioglitazone and 
bladder cancer used a composite referent group of all non-pioglitazone. Therefore, we chose 
to include composite referent groups in this example to empirically demonstrate the impact 
of this approach on the effect estimates. Although the inclusion of all non-users of the drug 
of interest in a referent group may increase power, effect estimates can be threatened by 
confounding by disease severity if there are major differences in disease severity between 
the drug of interest and the composite referent or its components.34,35 Furthermore, 
including untreated patients in the referent group can threaten validity further due to 
confounding by indication, since these patients are inherently different, especially if they 
either have less severe diabetes and are able to manage their diabetes without medical 
therapy (e.g., diet and exercise). As expected, the relative risk of bladder cancer for 
pioglitazone users compared to patients who entered the composite non-pioglitazone group 
as metformin users was greater than that of pioglitazone compared to the entire non-
pioglitazone referent group, because metformin is generally given at the earliest stage of 
diabetes severity per American Diabetes Association recommendation.39 We had expected 
there to be a decreased risk of bladder cancer when pioglitazone users were compared to the 
long-acting insulin users, given previous literature9 and the increased frequency of diabetic 
complications among long-acting insulin users. However, the long-acting insulin users in our 
sample were at decreased risk of bladder cancer. This is likely due to increased competing 
risk of death as they experienced differentially more deaths within the first 180 days after 
cohort entry. (Table S5)
This study used a hierarchical exposure classification as was done previously,6 searching the 
entire study period of interest to first identify pioglitazone users, then subsequently 
identifying other GLD use among those without use of the GLD of interest, and then lastly 
identifying untreated based on no occurrence of treatment during the entire period. The 
benefit of this design is that all pioglitazone users are included in the primary exposure 
group. However, looking into the future to determine cohort entry may impose immortal 
person-time bias if there are patients who enter the pioglitazone group after treatment with 
another GLD that are subsequently excluded due to prevalent bladder cancer that may be 
attributed to the other treatment.40,41 In this example, the majority of patients classified as 
pioglitazone users in the all-user comparison had prior exposure to another GLD (Table 1), 
and ~1% of pioglitazone users with prior GLD use were excluded due to prevalent bladder 
cancer. Therefore, the hierarchical design excluded bladder cancer cases attributable to the 
other GLD, lowering the incidence rate among the referent group.
This study has limitations that should be considered when interpreting results. First, 
although many of the design choices were implemented to be comparable to the 10-year 
safety study requested by the FDA,6 we were not able to completely emulate the previous 
study without a diabetic registry or 10 years of follow-up, among other data differences. 
Second, we did not have access to pathological confirmation of the bladder cancer outcome 
defined using claims. However, we used an algorithm previously validated for other solid 
tumors,30 and although we acknowledge potential misclassification, it is unlikely to be 
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differential between treatment groups. Third, we did not have clinical records or biomarkers 
(e.g. HbA1c) necessary to determine diabetic severity, but evaluated codes for diabetic 
complications indicative of diabetic severity (neuropathy, nephropathy, and retinopathy) and 
adjusted for these. The new-user comparisons that included multiple treatments had a 
substantial loss of power, but measured key covariates were balanced by design across 
treatment groups, also increasing the confidence about the balance of unmeasured 
covariates. Given that pioglitazone is often prescribed as second or in some cases third-line 
therapy, excluding prior use of any GLD among pioglitazone users excluded up to 96% of 
pioglitazone users, which increased the variance of the estimates. Excluding prior use of 
metformin excluded more than 50% of pioglitazone users. Fourth, under-report of 
medication use due to out-of-pocket purchases is possible, but assumed to be minimal. Fifth, 
a potential for detection bias has been suggested if pioglitazone users receive more 
urological work-up.42 However, since urinary tract-related comorbidities were similar across 
all comparisons, we do not suspect differentially more urological work-up among 
pioglitazone users. Furthermore, we previously evaluated the rate of urologic diagnostic 
procedures and found no differences in initiators of pioglitazone compared with initiators of 
DPP-4s or sulfonylureas.19 Lastly, to allow comparison with previously reported estimates, 
we only report relative estimates. Given that the incidence of bladder cancer is low, absolute 
risks are consistently small requiring almost 2,000 person-years of exposure to see one 
excess case of bladder cancer among new users of pioglitazone versus DPP-4. Therefore, 
relative risks may over-report actual harm.
Studies that exclude prevalent users and compare the initiation of the drug exposure of 
interest to the initiation of a clinically meaningful treatment alternative have been 
recommended for comparative effectiveness research to present the least biased comparison.
34–36,43 If a composite referent group is necessary due to power concerns, we caution against 
inclusion of metformin monotherapy users, long-acting insulin users, and untreated diabetic 
patients. In our example, the DPP-4 initiators were selected as the optimal comparator for 
pioglitazone initiators since DPP-4s are prescribed to patients similar to those prescribed 
pioglitazone.19,44 Although an approach that ignores treatment changes may be added, as-
treated estimates should be considered to minimize exposure misclassification for safety 
estimates. If there is reason to consider follow-up after end of exposure to allow for disease 
manifestation and diagnosis, such as with cancer outcomes, a latency period can be added to 
extend follow-up as necessary after treatment changes45.
Our study empirically demonstrates the effect of varying key parameters when evaluating the 
safety of diabetes drugs. The continued demand for new GLDs compels the need for more 
robust observational methods to improve the value of the RWE generation in order to equip 
clinicians to make informed prescribing decisions. Although there is no one-size-fits-all 
approach and recommendations may depend on the data source and the research question, 
we recommend that researchers consider how they define exposure, what they compare 
exposure to, and when they identify safety endpoints, as these methodological decisions may 
impact the interpretation of estimates.
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IT Initial-Treatment censoring approach
NDC National Drug Codes
NIGLD Non-Insulin Glucose-Lowering Drug
SGLT-2 Sodium-GLucose co-Transporter-2 inhibitors
TZD Thiazolidinedione
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Figure 1. Study flowchart showing cohorts varying referent choice and whether or not restricted 
to new users
DPP, dipeptidyl-peptidase-4; GLD, Glucose-Lowering Drug; NIGLD, Non-Insulin Glucose-
Lowering Drug; PIO, pioglitazone
1. PIO users that did not have ≥2 RX within 180 days were included in Referent #1, but 
excluded from Referent #2 and #5.
2. Number of PIO varies due to exclusion of prevalent users of the drugs of interest in each 
new-user comparison
Garry et al. Page 13














Fully-adjusted hazard ratios for relative bladder cancer incidence rates among pioglitazone 
users and each referent obtained using the multivariate Cox proportional hazards model that 
included age, age-squared, male sex, race (black, other, ref: white), cohort entry year (2008, 
2009, 2011, 2012, 2013, 2014, 2015, ref: 2010), smoking status, CHF, MI, stroke, prevalent 
cancer based on all available data, nephropathy, neuropathy, retinopathy, ACE, loop 
diuretics, statins, TZDs, DPP-4s, metformin, sulphonylureas, SGLT-2s, fast-acting insulin, 
long-acting insulin, other glucose-lowering drugs. ACE, angiotensin-converting enzyme 
inhibitor; CHF, congestive heart failure; CI, confidence interval; DPP, dipeptidyl-
peptidase-4; GLD, glucose lowering drug; HR, hazard ratio; MI, myocardial infarction; 
NIGLD, noninsulin glucose-lowering drug; PIO, pioglitazone; TZD, thiazolidinedione.
Garry et al. Page 14

























Garry et al. Page 15
Table 1.
Distribution (%) of patient characteristics among pioglitazone users & each referent - All User Cohorts
PIO Non-PIO PIO GLD PIO NIGLD PIO DPP
N 135,188 1,375,024 135,188 828,527 135,188 705,446 135,188 128,089
Demographics and Lifestyle at Cohort Entry
Age, mean (SD) 74.7 (6.7) 75.9 (7.7) 74.7 (6.7) 74.9 (7.3) 74.7 (6.7) 74.8 (7.2) 74.7 (6.7) 75.2 (7.1)
Age, median (IQR) 73 (69,79) 74 (69,81) 73 (69,79) 73 (69,80) 73 (69,79) 73 (69,80) 73 (69,79) 74 (69,80)
Male 43.6 40.3 43.6 41.3 43.6 41.7 43.6 41.8
White 74.3 78.7 74.3 78.5 74.3 79.1 74.3 77.5
Black 11.7 12.4 11.7 12.8 11.7 11.9 11.7 11.3
Other Race † 14.0 8.9 14.0 8.7 14.0 9.1 14.0 11.2
Index Year: 2008 50.6 34.7 50.6 41.3 50.6 39.3 50.6 13.8
Index Year: 2009 12.1 9.1 12.1 7.3 12.1 7.6 12.1 7.4
Index Year: 2010 11.1 8.0 11.1 6.7 11.1 7.0 11.1 8.2
Index Year: 2011 8.2 8.4 8.2 7.3 8.2 7.6 8.2 11.6
Index Year: 2012 4.2 8.7 4.2 7.9 4.2 8.1 4.2 13.5
Index Year: 2013 4.1 9.4 4.1 8.8 4.1 9.1 4.1 14.8
Index Year: 2014 6.8 14.1 6.8 13.8 6.8 14.3 6.8 21.0
Index Year: 2015 2.9 7.7 2.9 6.9 2.9 7.0 2.9 9.7
Smoking ‡ 7.7 12.3 7.7 11.4 7.7 11.1 7.7 13.1
Diabetic Complications
Nephropathy 8.4 6.0 8.4 7.7 8.4 5.8 8.4 10.3
Neuropathy 19.5 13.3 19.5 18.0 19.5 15.9 19.5 22.6
Retinopathy 19.3 10.6 19.3 15.5 19.3 13.2 19.3 17.3
Diabetic Medication Use
Thiazolidinediones 69.1 5.2 69.1 7.9 69.1 8.2 69.1 8.7
DPP-4 11.3 4.8 11.3 7.6 11.3 8.4 11.3 35.1
Metformin 57.3 29.6 57.3 46.9 57.3 52.8 57.3 62.5
Sulfonylureas 51.0 22.8 51.0 36.0 51.0 40.1 51.0 49.2
Other § 6.8 2.8 6.8 4.4 6.8 4.7 6.8 6.4
SGLT-2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.4
Fast-Acting Insulin 6.9 8.2 6.9 12.4 6.9 7.4 6.9 8.4
Long-Acting Insulin 16.8 15.6 16.8 23.8 16.8 15.6 16.8 18.1
Other Co-morbidities
CHF 15.6 23.0 15.6 21.8 15.6 18.8 15.6 23.0
COPD 14.1 19.9 14.1 18.0 14.1 16.7 14.1 17.7
MI 0.7 1.1 0.7 1.1 0.7 0.9 0.7 1.1
Stroke 10.0 12.9 10.0 11.9 10.0 10.6 10.0 11.8
History of Cancer ¶ 16.5 20.7 16.5 17.9 16.5 18.0 16.5 21.7
Medication Use
ACE 42.3 37.0 42.3 40.8 42.3 40.3 42.3 39.7
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PIO Non-PIO PIO GLD PIO NIGLD PIO DPP
N 135,188 1,375,024 135,188 828,527 135,188 705,446 135,188 128,089
ARB 18.5 15.8 18.5 16.5 18.5 16.1 18.5 19.8
Beta Blockers 42.7 47.3 42.7 47.5 42.7 46.2 42.7 50.6
CCBs 29.1 31.3 29.1 31.0 29.1 30.1 29.1 32.4
Loop Diuretics 23.7 27.4 23.7 28.2 23.7 25.1 23.7 28.5
Statins 66.2 51.1 66.2 54.8 66.2 55.1 66.2 56.7
ACE, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor blockers; CCB, Calcium Channel Blocker; CHF, Congestive Heart 
Failure; COPD, Chronic Obstructive Pulmonary Disease; DPP, dipeptidyl-peptidase-4; GLD, Glucose-Lowering Drug; IQR, interquartile range; 
NIGLD, Non-Insulin Glucose-Lowering Drug; PIO, pioglitazone; SD, Standard Deviation
†
Other race combines the following races as defined by Medicare: Other, Asian, Hispanic, or Native American
‡
Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor sensitivity (27.9% [95% CI: 16.6–39.1%])
§.
Other diabetic medications included alpha-glucosidase inhibitors, amylin analogs, Glucagon-like peptide-1s, and meglitinides.
¶
History of cancer was evaluated during all available data prior to cohort entry.
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Table 2.
Distribution (%) of patient characteristics among initiators of pioglitazone & each referent - New User 
Cohorts†)
PIO‡ Non-PIO PIO‡ GLD PIO‡ NIGLD PIO‡ DPP
N 5,752 675,986 5,752 172,663 7,547 174,512 33,551 76,503
Demographics and Lifestyle at Cohort Entry
Age, mean (SD) 75.4 (6.9) 76.8 (7.8) 75.4 (6.9) 75.2 (7.1) 75.4 (6.9) 75.0 (7.0) 74.9 (6.7) 75.7 (7.1)
Age, median (IQR) 74 (70,80) 76 (70,83) 74 (70,80) 74 (69,80) 74 (70,80) 73 (69,80) 74 (69,79) 74 (70,81)
Male 45.0 39.4 45.0 42.8 43.7 42.2 42.7 39.5
White 70.4 79.5 70.4 79.4 68.8 79.4 72.5 76.7
Black 11.8 11.3 11.8 11.2 14.0 11.1 11.7 11.1
Other Race§ 17.8 9.2 17.8 9.5 17.2 9.6 15.9 12.3
Index Year: 2008 26.5 20.3 26.5 12.8 26.0 12.6 23.2 7.7
Index Year: 2009 22.3 12.7 22.3 13.9 22.7 13.8 24.1 9.0
Index Year: 2010 16.2 11.1 16.2 12.9 16.9 12.8 19.4 10.1
Index Year: 2011 11.0 11.0 11.0 12.4 11.1 12.5 11.6 14.2
Index Year: 2012 4.9 10.6 4.9 11.8 4.9 12.0 4.6 15.8
Index Year: 2013 5.4 11.1 5.4 11.9 5.6 12.2 5.7 15.9
Index Year: 2014 5.9 14.0 5.9 13.0 5.9 13.6 6.7 17.2
Index Year: 2015 7.7 9.3 7.7 11.3 6.9 10.6 4.6 10.2
Smoking¶ 9.2 13.5 9.2 13.7 9.4 13.4 9.0 13.8
Diabetic Complications
Nephropathy 5.8 2.8 5.8 3.8 8.9 4.4 8.5 10.2
Neuropathy 10.1 5.5 10.1 8.3 16.0 10.4 19.3 22.6
Retinopathy 8.0 3.0 8.0 5.2 13.3 7.2 16.6 16.3
Diabetic Medication Use
Thiazolidinediones -- -- -- -- -- -- -- --
DPP-4 -- -- -- -- -- -- -- --
Metformin -- -- -- -- -- -- 60.3 61.7
Sulfonylureas -- -- -- -- -- -- 53.4 49.6
Other †† -- -- -- -- -- -- 5.4 5.6
SGLT-2 -- -- -- -- -- -- 0.2 0.2
Fast-Acting Insulin -- -- -- -- 13.3 8.2 8.2 9.1
Long-Acting Insulin -- -- -- -- 25.1 13.3 16.3 17.4
Other Co-morbidities
CHF 15.0 22.9 15.0 20.5 19.1 20.0 16.7 24.9
COPD 16.9 21.7 16.9 20.0 18.8 19.4 15.8 19.4
MI 0.8 1.2 0.8 1.1 0.8 1.1 0.8 1.2
Stroke 10.6 13.5 10.6 12.1 12.6 11.6 11.4 12.9
History of Cancer ‡‡ 18.8 24.4 18.8 22.4 19.6 22.2 19.8 24.2
Medication Use
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PIO‡ Non-PIO PIO‡ GLD PIO‡ NIGLD PIO‡ DPP
N 5,752 675,986 5,752 172,663 7,547 174,512 33,551 76,503
ACE 29.4 30.5 29.4 31.9 32.5 33.2 42.2 40.3
ARB 15.0 14.2 15.0 13.5 15.8 14.1 16.7 19.3
Beta Blockers 40.9 46.4 40.9 45.9 43.3 46.5 44.8 51.7
CCBs 28.9 31.5 28.9 30.6 31.0 30.7 31.7 34.0
Loop Diuretics 19.7 25.0 19.7 24.3 25.0 25.0 22.1 29.5
Statins 50.3 45.5 50.3 46.9 51.7 48.3 59.6 55.5
ACE, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor blockers; CCB, Calcium Channel Blocker; CHF, Congestive Heart 
Failure; COPD, Chronic Obstructive Pulmonary Disease; DPP, dipeptidyl-peptidase-4; GLD, Glucose-Lowering Drug; IQR, interquartile range; 
NIGLD, Non-Insulin Glucose-Lowering Drug; PIO, pioglitazone; SD, Standard Deviation
†
New use of GLD exposure was determined based on no prescription claims for the drug classes included in each comparison during the 365-day 
period prior to the initial claim.
‡
Number of people initiating PIO differs for each comparison due to exclusions of prior use of drugs included in comparison only.
§
Other race combines the following races as defined by Medicare: Other, Asian, Hispanic, or Native American
¶.
Smoking was defined using a validated algorithm that has nearly perfect specificity and PPV, but poor sensitivity (27.9% [95% CI: 16.6–39.1%])
††
Other diabetic medications included alpha-glucosidase inhibitors, amylin analogs, Glucagon-like peptide-1s, and meglitinides.
‡‡
History of cancer was evaluated during all available data prior to cohort entry
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